GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2020
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
2 registry-linked trialsAbstract readPractice Guideline
In one paragraph
Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 782 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
782citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients: the Study Protocol
Diagnostic Performance of F18-FDG PET/CT in Detecting Distant Metastases in Breast Cancer
Who cites it
782 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Progression-free survival prediction and comparative metastasis detection accuracy ofEuropean journal of nuclear medicine and molecular imaging · 2026Pooled it
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression.Frontiers in oncology · 2026Pooled it
- Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2- advanced breast cancer: from prognostic biomarker to clinical decision-making - a comprehensive review.Frontiers in oncology · 2026Pooled it
- Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.JNCI cancer spectrum · 2025Pooled it
- Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.Breast cancer research and treatment · 2025Pooled it
- Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.Breast cancer (Tokyo, Japan) · 2026Trial
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.Cell reports. Medicine · 2026Trial
- Dalpiciclib plus endocrine therapy in women with HRNature cancer · 2026Trial
- The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.International journal of clinical oncology · 2026Trial
- Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.Signal transduction and targeted therapy · 2026Trial
- Overall Survival with Inavolisib inThe New England journal of medicine · 2025Trial
- Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system.Journal of cancer research and clinical oncology · 2025Trial
- Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.Journal of hematology & oncology · 2025Trial
- Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer.ESMO open · 2025Trial
- Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.Cancer chemotherapy and pharmacology · 2026Article
- Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.Acta oncologica (Stockholm, Sweden) · 2026Article
- [The evolution of surgical management for early-stage breast cancer at a university breast centre in Hungary].Magyar onkologia · 2026Article
722 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
F CardosoBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
S Paluch-ShimonSharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel.
E SenkusDepartment of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
G CuriglianoDepartment of Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milan, Milan, Italy.
M S AaproBreast Center, Clinique de Genolier, Genolier, Switzerland.
F AndréDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
C H BarriosLatin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil.
J BerghDepartment of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden.
G S BhattacharyyaDepartment of Medical Oncology, Salt Lake City Medical Centre, Kolkata, India.
L BiganzoliDepartment of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy.
F BoyleThe Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia.
M-J CardosoBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal.
L A CareyDepartment of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
J CortésIOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Department of Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
N S El SaghirDivision of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
M ElzayatEuropa Donna, The European Breast Cancer Coalition, Milan, Italy.
A EniuInterdisciplinary Oncology Service (SIC), Riviera-Chablais Hospital, Rennaz, Switzerland.
L FallowfieldSHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK.
P A FrancisDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
K GelmonMedical Oncology Department, BC Cancer Agency, Vancouver, Canada.
J GligorovBreast Cancer Expert Center, University Cancer Institute APHP, Sorbonne University, Paris, France.
R HaidingerBrustkrebs Deutschland e.V., Munich, Germany.
N HarbeckBreast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany.
X HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
B KaufmanDepartment of Oncology, Sheba Medical Center, Ramat Gan, Israel.
R KaurBreast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia.
B E KielyNHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia.
S-B KimDepartment of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
N U LinSusan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
S A MertzMetastatic Breast Cancer Network, Inverness, USA.
S NeciosupDepartment of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru.
B V OffersenDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
S OhnoBreast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan.
O PaganiMedical School, Geneva University Hospital, Geneva, Switzerland.
A PratDepartment of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona; Department of Medicine, University of Barcelona, Barcelona.
F Penault-LlorcaDepartment of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France.
H S RugoBreast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
G W SledgeDivision of Oncology, Stanford School of Medicine, Stanford, USA.
C ThomssenDepartment of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany.
D A VorobiofOncology Research Unit, Belong.Life, Tel Aviv, Israel.
T WisemanDepartment of Applied Health Research in Cancer Care, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
B XuDepartment of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
L NortonBreast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
A CostaEuropean School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland.
E P WinerSusan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsConsensusHumansSocieties, MedicalABCadvancedbreast cancerESO-ESMOguidelinesmetastatic
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
NCT06161181ClinicalTrials.gov
NCT07523516ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.